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Background. Interest in the neuro-cognitive proﬁle of patients with schizophrenia and co-morbid obsessive com-
pulsive disorder (schizo-OCD) is rising in response to reports of high co-morbidity rates. Whereas schizophrenia has
been associated with global impairment in a wide range of neuro-cognitive domains, OCD is associated with speciﬁc
deﬁcits featuring impaired performance on tasks of motor and cognitive inhibition involving frontostriatal neuro-
circuitry.
Method. We compared cognitive function using the CANTAB battery in patients with schizo-OCD (n=12) and a
schizophrenia group without OCD symptoms (n=16). The groups were matched for IQ, gender, age, medication,
and duration of illness.
Results. The schizo-OCD patients made signiﬁcantly more errors on a task of attentional set-shifting (ID-ED set-shift
task). By contrast, no signiﬁcant diﬀerences emerged on the Stockings of Cambridge task, the Cambridge Gamble
Task or the Aﬀective Go/NoGo tasks. No correlation emerged between ID-ED performance and severity of schizo-
phrenia, OCD or depressive symptoms, consistent with neurocognitive impairment holding trait rather than state-
marker status. Schizo-obsessives also exhibited a trend toward more motor tics emphasizing a neurological contribution
to the disorder.
Conclusion. Our ﬁndings reveal a more severe attentional set-shifting deﬁcit and neurological abnormality that may
be fundamental to the neuro-cognitive proﬁle of schizo-OCD. The clinical implications of these impairments merit
further exploration in larger studies.
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Introduction
The term ‘schizo-obsessiveness ’ was coined byHwang
&Opler (1994) and refers to a dual diagnosis of schizo-
phrenia and obsessive compulsive disorder (OCD)
or obsessive compulsive symptoms (OCS). Although
large variance exists in the documented prevalence
rates of schizo-obsessive disorder, higher-than-
expected co-morbidity rates for OCD and schizo-
phrenia have ignited a controversy (Huppert & Smith,
2005). The prevalence of OCD in the general popu-
lation remains quite controversial ; however, it is cer-
tainly much lower (with estimates from 0.08 to 2.5%;
e.g. Fireman et al. 2001 ; Crino et al. 2005) than the
prevalence of OCD in schizophrenia, which has
estimates ranging from 0.5 to 59.2% both in ﬁrst-
episode and in chronic schizophrenia (Bland et al.
1987 ; Karno et al. 1988 ; Berman et al. 1995 ; Eisen et al.
1997 ; Poyurovsky et al. 1999a, 2000, 2003, 2006 ;
Bermanzohn et al. 2000 ; Kruger et al. 2000 ; Niehaus
et al. 2005 ; Mukhopadhaya et al. 2009) and for OCS in
schizophrenia the estimated prevalence is similarly
between 3.5 and 46% (Rosen, 1957 ; Myers et al.
1984 ; Fenton & McGlashan, 1986 ; Berman et al. 1995,
1998 ; Lysaker et al. 2000 ; Tibbo et al. 2000 ; Fabisch
et al. 2001). It remains unclear if this reﬂects a true co-
morbidity, more severe illness or perhaps a unique
diagnostic subcategory of schizophrenia.
A distinct neuro-anatomical proﬁle has also been
associated with schizophrenia and co-morbid OCD
(schizo-OCD). Magnetic resonance imaging studies
have identiﬁed signiﬁcantly reduced volumes in the
left hippocampus, frontal lobes (Aoyama et al. 2000)
and anterior horn of the lateral and third ventricle
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(Goldstein et al. 1999) for schizophrenia patients with
OCS when compared with their schizophrenia coun-
terparts without OCS. Additionally, schizo-obsessive
patients show more neurological signs (Sevincok et al.
2004), motor symptoms including catatonia, loss of
motor ability or hyperactive motor activity (Tibbo et al.
2000) and extrapyramidal symptoms (Kruger et al.
2000 ; Ohta et al. 2003 ; Mukhopadhaya et al. 2009)
compared with schizophrenia subjects ; and more tics
when compared with patients with OCD (Poyurovsky
et al. 2006). However, not all studies have found
more neurological or motor symptoms in schizo-OCD
compared with OCD (Poyurovsky et al. 2007). Schizo-
phrenia patients with OCS have higher levels of
positive and emotional discomfort symptoms on the
Positive and Negative Syndrome Scale (PANSS) com-
pared with patients without OCS (Hwang et al. 2000 ;
Lysaker et al. 2000 ; Tibbo et al. 2000), they tend to
have a poorer prognosis (Fenton and McGlashan,
1986), poorer treatment outcomes (Lysaker et al. 2004)
and more severe impairment of social functioning
(Poyurovsky et al. 2001 ; Lysaker et al. 2004). Although,
not all studies have found a poorer prognosis in terms
of global functioning and illness severity (Rajkumar
et al. 2008) or more positive and negative symptoms
on the PANSS compared with patients without OCD
(Byerly et al. 2005 ; Poyurovsky et al. 2006 ; Rajkumar
et al. 2008). With the addition of selective serotonin re-
uptake inhibitors (SSRIs), symptoms such as agi-
tation and psychosis have been observed in schizo-
obsessives (Lindenmayer et al. 1990 ; Zohar et al.
1993 ; Berman et al. 1995 ; Bermanzohn et al. 1997 ;
Poyurovsky et al. 1999b) suggesting that in this sub-
group the symptoms of OCD may be more diﬃ-
cult to treat with pharmacotherapy. Furthermore,
Mukhopadhaya et al. (2009) reported that schizo-OCD
cases treated with SSRIs showed greater levels of
extra-pyramidal side eﬀects compared with untreated
counterparts. Finally, schizo-obsessives are greater
health service users compared with subjects with
schizophrenia (Berman et al. 1995) and have a longer
duration of hospitalizations (Fenton & McGlashan,
1986 ; Berman et al. 1995 ; Hwang et al. 2000). Clariﬁ-
cation of the neuro-biological status of schizo-OCD
may prompt modiﬁcation of existing treatment stra-
tegies or even the development of new targeted treat-
ments for this prominently disabled group.
Neuropsychological assessment using standardized
neuro-cognitive tasks with well understood neural
underpinnings may be one way of evaluating the dif-
ferent neural contributions to schizophrenia with
OCD. Patients with schizophrenia show deﬁcits re-
lative to controls across a wide range of neuro-
psychological domains including memory, language,
attention and executive function (Fioravanti et al.
2005). The Cambridge Automated Neuropsychologi-
cal Test Battery (CANTAB) is a well-established com-
puterized neuropsychological touch-screen test battery
that examines a range of neuro-cognitive functions,
including tests tapping the frontal lobes and their sub-
cortical connections. To date no published literature
exists on the use of CANTAB in schizo-OCD; how-
ever, patients with ‘schizophrenia only’ and ‘OCD
only’ have been found to be impaired on tasks derived
from the CANTAB (see Table 1), implying this battery
has utility in evaluating this patient group.
The intra- and extra-dimensional (ID-ED) phases of
the ID-ED set-shift test assess reversal learning and
set-shifting respectively. In humans, the former task is
thought to depend upon the integrity of orbitofrontal
neuro-circuitry and, the latter, ventro-lateral prefrontal
cortex circuits (Hampshire & Owen 2006). Compared
with healthy controls, patients with schizophrenia ex-
hibit signiﬁcant deﬁcits that include high levels of
perseverative errors on both elements of the task
(Elliott et al. 1998 ; Tyson et al. 2004 ; Ceaser et al. 2008).
The Stockings of Cambridge (SOC; computerized
version of Tower of London) task assesses planning
and thinking and is thought to involve the dorsolateral
prefrontal cortex. Patients with schizophrenia typi-
cally make fewer perfect solutions and more moves on
the SOC task (Pantelis et al. 1997 ; Elliott et al. 1998 ;
Hutton et al. 1998 ; Tyson et al. 2004 ; Braw et al. 2008).
The Cambridge Gamble Task (CGT) of decision mak-
ing and impulsivity is sensitive to the integrity of or-
bitofrontal neuro-circuitry (Rahman et al. 1999 ; Rogers
et al. 1999 ; Murphy et al. 2001). Patients with schizo-
phrenia exhibit longer decision-making latencies and
poorer decision making (Hutton et al. 2002). The
Aﬀective Go/NoGo (AGN) task is also sensitive to
orbitofrontal cortex function and assesses information-
processing biases for positive and negative stimuli and
response inhibition (Murphy et al. 1999). We are not
aware of any studies that have used the AGN task in
patients with schizophrenia (for a review of the use of
CANTAB in schizophrenia, see Levaux et al. 2007). The
speciﬁcity of the purported relationships between task
performance and the frontal lobes requires further
examination in schizophrenia using imaging tech-
niques. However, a meta-analytic review of imaging
studies has conﬁrmed the presence of ‘hypofrontality ’
in schizophrenia patients, both for resting and cogni-
tive challenge studies (see Hill et al. 2004).
OCD patients also show impaired performance on
tasks associated with frontostriatal function. On the
ID-ED set-shift task, deﬁcits have been reported both
on the intra- (Veale et al. 1996 ; Purcell et al. 1998a) and
extra-dimensional set-shift phases (Veale et al. 1996 ;
Chamberlain et al. 2006a). In the study by Chamberlain
et al. (2007b), extra-dimensional (ED) impairment was
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unrelated to symptom severity and endured despite
treatment. Moreover, non-aﬀected relatives exhibited
the same abnormalities, suggesting a trait marker re-
ﬂecting genetic vulnerability to OCD. Chamberlain
et al. (2007b) proposed that the inability to shift atten-
tional focus may result in cognitive inﬂexibility and
contribute to the generation of compulsive symptoms.
Purcell et al. (1998a, b) found that compared with con-
trols, OCD patients spent more time engaged in move-
ments on the SOC test, suggesting motor initiation
and execution problems, but they showed no increase
in thinking latencies nor increased error rates. In
contrast, Veale et al. (1996) reported that OCD patients
spend more time generating alternative strategies fol-
lowing an incorrect move on the same task. Similarly,
Chamberlain et al. (2007a) found the OCD group made
more attempts to correct solution on the SOC task.
A functional magnetic resonance imaging (fMRI)
study using the SOC found poorer planning in OCD
patients, which was associated with decreased dorso-
lateral prefrontal cortex and caudate nucleus activity
when compared with controls (van den Heuvel et al.
2005). Unlike patients with schizophrenia, how-
ever, individuals with OCD do not exhibit abnormal
performance on the CGT (Watkins et al. 2005 ;
Chamberlain et al. 2007a), although they make more
omission errors for sad words than matched controls,
suggesting a selective attentional bias toward negative
stimuli (Chamberlain et al. 2007a).
Given the literature outlined above, we might ex-
pect that compared with patients with schizophrenia,
schizo-obsessive patients would perform signiﬁcantly
poorer on tasks tapping frontostriatal function (known
to be impaired in OCD such as the ID-ED and SOC
tests). We also expected to ﬁnd no diﬀerences between
schizo-obsessives and schizophrenics on tasks linked
to orbitofrontal function (such as the CGT and AGN
tests). Our secondary aim was to investigate if the de-
gree of cognitive impairment correlated with clinical
measures. Consistent with neuro-cognitive impair-
ment holding trait rather than state marker status, we
hypothesized that no correlation would emerge with
severity of schizophrenia, OCD or depressive symp-
toms. Nonetheless, we did expect a positive corre-
lation between neuro-cognitive impairment and
severity of neurological signs as we hypothesized that
the latter also represented a trait marker of illness.
Method
Participants
A total of 28 patients (22 male, six female) with a pri-
mary DSM-IV diagnosis of schizophrenia were re-
cruited from a local National Health Service Trust. The
patients were aged between 20 and 67 years [mean
37.7, standard deviation (S.D.)=11.7]. All had chronic
schizophrenia and were medicated with the atypical
antipsychotic clozapine. Patients who were unable to
give informed consent or had current alcohol or illicit
drug dependence or a history of head injury were
speciﬁcally excluded. The 28 patients were categor-
ized into two groups based on diagnosis using the
Mini International Neuropsychiatric Inventory (MINI;
Sheehan et al. 1998) and careful screening for OCS by a
psychiatrist experienced in the recognition and treat-
ment of OCD using a detailed clinical interview sup-
plemented by the Yale Brown Obsessive Compulsive
Scale and Checklist (YBOCS; Goodman et al. 1989a, b).
Patients who formed the schizo-OCD group (n=12)
fulﬁlled DSM-IV criteria for schizophrenia and OCD;
the remaining 16 patients had only a DSM-IV diag-
nosis of schizophrenia. The study was approved by
the local ethics committee and all participants gave
written consent to participate.
Clinical measures
All participants were administered the following
clinical scales : MINI (Sheehan et al. 1998) ; YBOCS
(Goodman et al. 1989a, b) ; Clinical Global Impression
Scale for schizophrenia (CGI-Sch ; Haro et al. 2003) ;
Sheehan Disability Scale (SDS; Sheehan et al. 1996)
and the Montgomery–A˚sberg Depression Rating Scale
(MADRS; Montgomery & A˚sberg, 1979).
Neurological measures included: Abnormal In-
voluntary Movement Scale (AIMS; Guy, 1976) ; Simp-
son Angus Scale (SAS; Simpson & Angus, 1970) ;
Neurological Evaluation Scale (NES; Buchanan and
Heinrichs, 1989) ; Yale Global Tic Severity Scale
(YGTSS; Leckman et al. 1989), Meta-cognition Ques-
tionnaire (MCQ-30 ; Wells & Cartwright-Hatton, 2004).
The MCQ-30 measures individual diﬀerences in a
selection of meta-cognitive beliefs, judgements and
monitoring tendencies.
Neuropsychological measures
Patients were administered the National Adult
Reading Test (NART) (Nelson, 1982) and four tests
from the CANTAB (see below), two of which were
chosen to evaluate neuro-cognitive functioning be-
lieved to depend upon frontostriatal neuro-circuitry
(ID-ED, SOC) and two to measure neuro-cognitive
function subserved by orbitofrontal circuits (CGT,
AGN). The order of the neuropsychological tasks was
counterbalanced in each group.
Intra–extra dimensional set-shift task. During the con-
ceptually crucial extra-dimensional shift (EDS) stage,
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Table 1. Neuropsychological performance on CANTAB tests in patients with schizophrenia and OCD
Task
Schizophrenia v. Control OCD v. Control
Author Findings Author Findings
ID-ED Elliott et al. 1995 More perseverative errors Veale et al. 1996 More failures at each stage
Pantelis et al. 1999 More errors at IDS and EDS Purcell et al. 1998a IDS lower score
Shamay-Tsoory et al.
2007
More trials to reach criterion at
ID reversal, EDS and ED reversal
Chamberlain et al. 2006a More trials to reach criterion
on ED shift trials
Joyce et al. 2002 75% of patients were unable to
perform an EDS
Purcell et al. 1998b No diﬀerence on IDS and EDS
trial scores
Hutton et al. 1998 First episode schizophrenia patients had intact
ability to switch attention
Nielen & den Boer 2003 Require same number of trials to complete
the task, no diﬀerence in ID or ED errors
Tyson et al. 2004 Fewer stages reached, more errors
up to ED S and at EDS
Watkins et al. 2005 More errors at ED stage, more
patients failed to complete all stages
Jazbec et al. 2007 Selective diﬃculties on C_D and
EDS stages
Fenger et al. 2005 Deﬁcit in shifting attention, reversing response,
performed more poorly on IDS and EDS trials
Braw et al. 2008 More errors, fewer stages
completed
Chamberlain et al. 2007b More trials to reach criterion
on EDS trials
Elliott et al. 1998 More errors, more perseverative errors on EDS
and IDS
SOC Pantelis et al. 1997 More moves, fewer perfect solutions, longer to
execute, longer subsequent thinking time
Veale et al. 1996 Longer generating solutions,
more errors at each stage
Elliott et al. 1998 Fewer correct on higher move
problems
Purcell et al. 1998a Longer initial movement time,
longer subsequent movement time
Joyce et al. 2002 More failures at ED stage, reached
lower stages
Watkins et al. 2005 One touch SOC found intact
planning ability
Tyson et al. 2004 Solved fewer minimum move problems Purcell et al. 1998b Longer, initial and subsequent
movement times
Braw et al. 2008 Longer initial thinking times,
longer subsequent thinking times, solved
fewer problems in minimum moves
Chamberlain et al. 2006b Lower strategy scores, generated
fewer novel sequences after training
Pantelis et al. 1997 Fewer perfect solutions, required
more moves for completion, slower movement
times and slower subsequent thinking latencies
Nielen and Den Boer, 2003 Fewer minimum move solutions,
longer subsequent thinking time and longer time
spent initiating and completing one sequence
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divergent thinking is required in order to shift atten-
tion away from a previously correct stimulus dimen-
sion to a novel (previously irrelevant) one. The total
number of errors on the ID-ED and the number of
errors at the EDS stage were used as the principal
measures of attentional set-shifting.
Stockings of Cambridge. The SOC assesses spatial
planning andmotor control and is essentially a version
of the Tower of London task. The trial evaluates
executive planning that involves placing balls in
sockets to match a given pattern within a speciﬁed
number of moves. A low score on the measure
‘number of problems solved in minimum moves’ re-
ﬂects an individual’s inability to plan ahead.
Cambridge Gamble Task. This task assesses impulse
control, risk-taking behaviour and decision making.
The participant is presented with a row of boxes across
the top of the screen, some of which are coloured
red and others blue. Participants start by guessing
whether a token is hidden in a red or blue box. In the
gambling stages, subjects are given 100 points and can
place a bet on the location of the token (either rising
or falling oﬀers) based on their conﬁdence. The ratio
of red:blue boxes is manipulated to present diﬀerent
levels of uncertainty of winning and the aim is to ac-
cumulate as many points as possible. A higher score
on the CGT risk-taking measure is indicative of more
risk taking. The task also measures the average latency
to make the decision when placing bets.
Aﬀective Go-NoGo Task. The AGN assesses mood-
processing bias. A series of words, either positive or
negative, are rapidly presented in the middle of the
screen. The participant is given a target category, e.g.
positive, and is asked to respond whenever they see a
word that matches the category. The AGN total omis-
sions measure (e.g. failure to respond to sad words
in sad word blocks) was used to measure response
inhibition, where more errors would be indicative of
motor impulsivity, i.e. an inability to inhibit motoric
responses ; mean correct latency was also recorded.
Statistical analyses
The distributions for all data were examined using
the Kolmogorov–Smirnov statistic. Where normality
could not be assumed, suitable transformations were
applied (arcsine, log and square root) for proportional
measures from the CGT and latency measures for the
SOC and AGN tasks. All analyses were run with and
without clozapine dose entered as a covariate ; how-
ever, it made no diﬀerence to the pattern of results and
the latter are reported here. The statistical tests wereC
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conducted with multivariate analysis of variance
(MANOVA) using SPSS version 16 (SPSS Inc., USA). A
conventional alpha value of 0.05 was used throughout
our analysis.
Results
Clinical measures
According to the CGI-Sch, the global severity of
schizophrenia was assessed as mild–moderate in both
groups with no between-group diﬀerences (values are
given as mean¡S.D.) (3.25¡1.05 v. 2.75¡1.44, F=1.3,
N.S.). The YBOCS revealed a moderate severity of OCD
in the schizo-OCD group when compared with the
patients with schizophrenia alone (18¡9.6 v. 2.4¡6.7).
The schizo-OCD group scored signiﬁcantly higher
than the schizophrenia patients for both their obsess-
ive and compulsive ratings (see Table 2). MADRS
(Montgomery & A˚sberg, 1979) scores (9.64¡7.77
v. 11.0¡10.73) indicate that neither patient group
was clinically depressed. Patients with schizo-OCD
were prescribed more SSRI, 50% v. 33.3%, but this
was not signiﬁcant [x2=0.77(1), N.S.]. Similarly, there
was no diﬀerence in usage of other anti-psychotics
[x2=0.13(1), N.S.], mood stabilizers [x2=0.791(1), N.S.]
or anti-muscarinics [x2=0.05(1), N.S.] between groups.
The YGTSS score was signiﬁcantly higher in schizo-
obsessives than schizophrenia counterparts [YGTSS:
F (1, 25)=5.84, p<0.02, gp2=0.18]. No signiﬁcant dif-
ferences were revealed on the MADRS, SDS, SAS or
NES (see Table 3).
Table 2. Clinical characteristics in schizo-obsessive disorder and schizophrenia
Schizo-obsessive Schizophrenia
Mean (S.D.) Mean (S.D.)
Males (n) 10 12
Females (n) 2 4 F<1
Age (years) 36.0 (10.7) 37.9 (12.7)
Age of onset (years) 23.3 (11.1) 26.1 (9.6) F<1
Duration of illness (years) 12.7 (5.2) 11.7 (8.6) F<1
NART IQ 103.5 (5.0) 103.1 (6.4) F<1
Clozapine (mg) 475.0 (238.0) 313.83 (125.0) F=5.1,
p=0.03
S.D., Standard deviation ; NART, National Adult Reading Test.
Table 3. Clinical measures for schizo-obsessive and schizophrenia groups
Clinical measures
Schizo-obsessive Schizophrenia
ANOVAMean (S.D.) Mean (S.D.)
Montgomery A˚sberg Depression
Rating Scale
9.64 (7.77) 11.00 (10.73) F<1, N.S.
Sheehan Disability Scale 11.63 (8.40) 11.50 (7.50) F<1, N.S.
Simpson–Angus Scale 2.00 (2.00) 2.12 (2.16) F<1, N.S.
Clinical Global Impression Scale
for Schizophrenia
3.25 (1.05) 2.75 (1.44) F=1.3, N.S.
Neurological Evaluation
Scale
17.00 (7.94) 12.00 (7.50) F=2.69, p=0.11
Abnormal Involuntary Movement Scale 8.54 (6.38) 5.34 (2.77) Z=1.84, p=0.06
Total Yale Global Tic Severity 9.92 (15.08) 0.50 (1.87) Z=2.6, p=0.04
YBOCS
Total 18.0 (9.6) 2.43 (6.8) Z=3.9, p<0.001
Obsessions 8.5 (5.0) 1.3 (3.6) Z=3.6, p<0.001
Compulsions 9.5 (4.7) 1.1 (3.1) Z=3.9, p<0.001
ANOVA, Analysis of variance ; N.S., non-signiﬁcant ; YBOCS, Yale Brown Obsessive Compulsive Scale and Checklist.
Where variables had non-normal distributions, Mann–Whitney U tests were used.
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Neuropsychological diﬀerences
A MANOVA revealed one signiﬁcant group dif-
ference (see Table 4) with schizo-obsessives, making
signiﬁcantly more total errors on the ID-ED task
(F1,26=6.86, p=0.015, gp2=0.21 : mean 34.92 v. mean
23.56).
Intra- and extra-dimensional performance
To investigate which elements of the ID-ED task were
more diﬃcult for schizo-obsessives, a MANOVA was
conducted to test for diﬀerences in the number of er-
rors made at each stage of the task between the schizo-
obsessive and the schizophrenia groups (Fig. 1). We
found a signiﬁcant diﬀerence between the number
of errors made speciﬁcally at the ED stage with sig-
niﬁcantly more errors made by the schizo-obsessive
group (F1,26=4.03, p=0.05, g2=0.13). There was no
signiﬁcant diﬀerence between the number of errors
on the extra-dimensional shift reversal (EDSR) stage
between the two groups (F1,26=2.96, p=0.09).
Relationships between neuropsychological function
and clinical symptoms
Correlational analyses revealed no evidence of a
relationship between neuro-cognitive performance
on the ID-ED and measures of schizophrenia symp-
tom severity (CGI), depression (MADRS), or OCD
(YBOCS) – all r<0.2, all N.S.
Relationships between neuropsychological function
and neurological symptoms
In the schizo-obsessive group, correlational analysis
revealed that increased severity of motor tics, as
measure d by the YGTSS, positively correlated with
CGT decision latency (r=0.65, n=11, p=0.03). There
was no further evidence of a relationship between
neuro-cognitive measures (ID-ED, SOC, CGT, AGN)
and neurological measures (YGTSS, SAS, Barnes
Akathisia Determination Scale, AIMS) in either group.
Table 4. Performance on neuropsychological measures for schizo-obsessive and schizophrenia groups
Test
Schizo-obsessive Schizophrenia
F value Eﬀect sizeMean (S.D.) Mean (S.D.)
ID-ED total errors 34.92 (8.00) 23.56 (13.28) F=6.86, p=0.015 g2=0.21
SOC problems solved in
minimum moves
5.75 (1.49) 7.07 (2.71) F=2.72, p=0.14 g2=0.08
CGT risk taking 0.54 (0.17) 0.48 (0.17) F<1, N.S. g2=0.03
CGT decision latency 4.95 (3.41) 4.80 (2.86) F<1, N.S. g2=0.00
AGN total omissions 30.00 (28.34) 33.13 (28.98) F<1, N.S. g2=0.00
AGN latency 5.12(1.13) 5.69 (1.16) F=1.25, p=0.28 g2=0.06
MCQ-30 total 31.42 (14.94) 35.94 (16.53) F<1, N.S. g2=0.02
For deﬁnitions of abbreviations, see Table 1 ; MCQ-30, Meta-Cognition Questionnaire.
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Fig. 1. (a) Mean intra- and extra-dimensional errors on each
block for schizo-obsessive (sz-obs ; –’–) and schizophrenia
(sz ; - - -%- - -) groups (error bars are standard error) ;
(b) percentage of sz-obs (–’– ; n=12) and sz (–&– ; n=16)
patients passing each stage of the intra- and extra-
dimensional task. sd, simple discrimination ; sr, simple
reversal ; cda, compound discrimination adjacent ; cds,
compound discrimination superimposed ; cr, compound
reversal ; ids, intra-dimensional shift ; idsr, intra-dimensional
shift reversal ; eds, extra-dimensional shift ; edsr,
extra-dimensional shift reversal.
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Discussion
As predicted, schizo-obsessive patients performed
signiﬁcantly poorer on the ID-ED set-shift task, which
is thought to reﬂect frontostriatal function, though not
on the SOC task, whereas no diﬀerence in performance
was found between schizo-obsessives and schizo-
phrenics on tasks thought to probe orbitofrontal func-
tion (CGT and AGN). Also, as expected, there was no
correlation between ID-ED impairment and severity
of schizophrenia, OCD or depressive symptoms, con-
sistent with neuro-cognitive impairment holding trait
rather than state-marker status. The two groups were
well matched in terms of severity of schizophrenia,
demographics, treatment and other clinical features,
apart from motor tics. The absence of clinically rel-
evant depression in either group minimized another
possible confound. Thus, the observed diﬀerences in
neuro-cognitive performance are probably attributable
to the fact that one group had co-morbid OCD and
the other did not. Motor tics were over-represented
in the schizo-OCD group and were related to longer
decision latencies on the CGT. We were unable to
demonstrate a correlation between performance on
other neuro-cognitive measures and severity of motor
or neurological signs. A single signiﬁcant correlation
may simply reﬂect a chance ﬁnding. However, con-
sidering the results from the study by Watkins et al.
(2005), in which patients with Tourette’s syndrome
showed greater impairment on decision-making tasks,
compared with OCD and normal controls, such a re-
sult could have been expected and may represent a
neuro-cognitive marker related to the presence of
motor tics.
The patients in this study were taking clozapine,
which is less likely than other antipsychotics to induce
extra-pyramidal adverse eﬀects that might confound
neuro-cognitive performance. We judge that these
factors are likely to have enhanced the validity and
thus the generalizability of our results for this group of
schizophrenia patients. Nevertheless, it is important to
acknowledge that our results refer to antipsychotic-
resistant cases that are receiving clozapine and they
therefore cannot necessarily be generalized to all cases
of schizophrenia. Additionally, an intriguing literature
suggests that antipsychotics may actually induce ob-
sessive symptoms in patients with schizophrenia (see
reviews by Fineberg et al. 2006 ; Mukhopadhaya et al.
2009) and has been estimated to occur in as many as
46.4% of those treated with clozapine (Anil et al. 2002,
Galvez-Buccolini et al. 2004). If this were to be the case,
then we might infer that the obsessions and compul-
sions in our cases were not representative of arche-
typal OCD. This hypothesis, however, has yet to
be substantiated in the context of a prospectively
designed, controlled longitudinal study and is hard
to integrate with other published data showing
that antipsychotics produce anti-obsessional eﬀects in
schizophrenia and that adjunctive antipsychotics are
clinically eﬀective in treatment-resistant OCD. More-
over, we note that OCS were noted in patients with
schizophrenia long before the advent of psychotropic
medications (Berrios, 1989) and, as far back as Bleuler
(1911), the similarities of delusions and obsessions
were noted. All of our patients were medicated with
clozapine (i.e. regardless of whether or not they ex-
hibited OCD symptoms).
Other explanations for the high rates of OCD ob-
served in clozapine-treated patients have also been
put forward, including : that OCD is a naturally
occurring sub-syndrome within the schizophrenia
spectrum, i.e. schizo-obsessives who have a genetic
liability for both schizophrenia and OCD (Poyurovsky
et al. 2003, 2004 ; Kayahan et al. 2005) ; that treatment
with atypical antipsychotics (such as clozapine) may
unmask OCD previously hidden by schizophrenic
symptoms (Ertugrul & Demir 2005) ; or that some, as
yet unidentiﬁed, factor may predispose individuals
both to OCD and to schizophrenia. Thus, greater levels
of illness co-morbidity might be predicted in such
patients. In a cross-sectional survey of 59 cases of
clozapine-treated illness, Mukhopadhaya et al. (2009)
did not ﬁnd that the point prevalence of OCD (24%)
was elevated in clozapine-treated cases compared
with other antipsychotics. We note that inclusion of a
matched OCD control group in this study might have
shed light on this question by helping tease apart dif-
ferent neuro-cognitive aspects of these disorders.
Schizo-obsessives made signiﬁcantly more ID-ED
errors compared with a matched group with schizo-
phrenia. Inspection of ID-ED errors at each of the
nine stages showed schizo-obsessives separated from
schizophrenics at the twomost diﬃcult stages of atten-
tional set-shift, i.e. EDS, in which the relevant stimulus
dimension alters, and EDS reversal, in which a rule
learnt needs to be inhibited and reversed. The EDS
stage is the critical stage of the ID/ED and is thought
to represent the category shift in the Wisconsin Card
Sorting Test (WCST) (Downes et al. 1989). The number
of errors made at this stage represents attentional set-
shifting ability.
There was no evident relationship between ED im-
pairment and schizophrenia or OCD symptom sever-
ity, and the deﬁcits endured despite treatment with
SSRI in 74% of cases with schizo-OCD, implying trait
rather than state-marker status. fMRI research evi-
dence suggests ED shifting in normal volunteers in-
volves ventro-lateral prefrontal cortex circuits, which
are believed to subserve ‘cognitive ﬂexibility ’ or
‘cognitive inhibition’ (Hampshire & Owen, 2006).
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One can hypothesize how deﬁcits in cognitive ﬂexi-
bility are linked to OCD phenomenology (i.e. ob-
sessions or compulsions) as OCD patients are unable
to shift from one thought or action to another or stop
thoughts entering their head unbidden. Hence, cog-
nitive inﬂexibility may represent a candidate endo-
phenotype, i.e. an inherited vulnerability factor for
schizo-OCD. Evidence that set-shifting may act as a
neuro-cognitive endophenotype for schizophrenia per
se comes largely from the WCST and is somewhat
mixed, with unaﬀected relatives of individuals with
schizophrenia not consistently manifesting poorer
WCST performance than controls (Kremen & Hoﬀ,
2004). Similar negative ﬁndings from the ID-ED task in
schizophrenic patients without documented OCD,
recently reported by Ceaser et al. (2008), cast further
doubt on ED shift deﬁcits representing a familial trait
marker for schizophrenia and imply such impairment
relates to the co-occurrence of OCD.
This is the ﬁrst study to examine ID-ED shifting in
schizo-OCD. Impairment in ED set-shifting has been
identiﬁed in tic-free OCD patients with predominantly
washing and checking rituals and their unaﬀected
ﬁrst-degree relatives (Chamberlain et al. 2006b,
2007a, b) and in patients with OCD plus obsessive
compulsive personality disorder (Fineberg et al. 2007).
Our ﬁndings are also consistent with results reported
by Watkins et al. (2005), who identiﬁed selective
ED deﬁcits in OCD outpatients, and Veale et al. (1996),
who found that OCD in-patients made more errors
than controls on multiple stages of the ID-ED task.
Further exploration of ID-ED performance in unaﬀec-
ted relatives of schizo-OCD probands may help clarify
whether ED shifting represents an inherited vulner-
ability factor for an obsessive compulsive syndrome
occurring in combination with schizophrenia.
Previous neuropsychological studies into schizo-
OCD have used the WCST as a test of attentional set-
shifting. A survey of the literature identiﬁed ﬁve
relevant studies (totalling 80 schizo-obsessives and
149 schizophrenics ; see Table 5) and the eﬀect sizes
reveal that schizo-obsessives sort fewer WCST cate-
gories than schizophrenics. Nevertheless, the mean
eﬀect size was small (d=0.20, 95% conﬁdence interval
x0.02 to 0.50) and non-signiﬁcant, almost certainly
because of the limited number of studies (K=5) in the
meta-analysis and because only one study produces a
large eﬀect (Ongur & Goﬀ, 2005).
The WCST can be criticized for its non-speciﬁc
nature, tapping a wide range of other neuro-cognitive
processes aside from attentional set-shifting, such
as error-based learning, feedback processing and
working memory (Laws, 1999). In this respect, we
believe the ID-ED task represents a more speciﬁc
test of attentional set-shifting that has been ana-
tomically localized, at least in normal volunteers, to
circuits involving the ventro-lateral prefrontal cortex
(Hampshire & Owen, 2006). The ﬁndings from this
small meta-analysis, however, suggest a similar pat-
tern of deﬁcits to that found in our study, thereby
providing further support for a more severe set-
shifting deﬁcit signifying a cognitive marker in schizo-
OCD patients. Nevertheless, we also note that like
WCST performance, performance on the ID-ED set-
shifting task is related to current intellectual function-
ing (for a review, see Laws 1999). Although our two
patient groups were matched on estimated pre-
morbid NART IQ, we cannot eliminate the possibility
that the schizo-obsessive group had undergone a
greater deterioration in current IQ.
Tics, which commonly occur together with OCD,
were a clinical sign that diﬀerentiated schizo-OCD
from schizophrenia with higher scores for motor tics
observed on the YGTSS, representing greater severity
of tic-related disorder compared with the schizo-
phrenia group. Additionally, we found a trend diﬀer-
ence for abnormal involuntary movements being
greater in the schizo-obsessive group. Our ﬁndings,
therefore, accord with previous studies that have
found evidence for more severe motor impairment in
Table 5. Mean eﬀect sizes of WCST categories completed from neuropsychological studies
in schizo-OCD
Study Samples Eﬀect size (d)
Lysaker et al. (2000) Sz with OCS (n=21), Sz (n=25) 0.00
Lysaker et al. (2002) Sz/schizo-aﬀective with OCD (n=11),
without OCD (n=52)
0.35
Hermesh et al. (2003) Sz-obs (n=21), Sz (n=19) x0.09
Whitney et al. (2004) Sz-obs (n=26), Sz (n=28) 0.08
Ongur & Goﬀ (2005) Sz-obs (n=14), Sz (n=79) 1.06
WCST, Wisconsin Card Sorting Test ; schizo-OCD, schizophrenia and co-morbid
obsessive compulsive disorder.
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the schizo-OCD proﬁle (Kruger et al. 2000 ; Ohta et al.
2003 ; Mukhopadhaya et al. 2009).
What do our results say about the nosology of
schizo-OCD? Compared with patients with schizo-
phrenia, patients with schizo-OCD showed more se-
vere deﬁcits limited to domains previously reported
for non-co-morbid OCD. Our study, therefore, sug-
gests a neuro-cognitive overlap between OCD and
schizophrenia and a ‘ true’ co-morbidity of two sep-
arate disorders. Application of a wider range of tests
in future studies may identify additional neuro-
cognitive features that are unique to schizo-OCD,
which would challenge this concept. Our results also
suggest that the neuro-cognitive proﬁle associated
with tic-related OCD co-morbid with schizophrenia
resembles that reported for the ‘archetypal ’ form
of OCD (washers and checkers without tics)
(Chamberlain et al. 2006a, 2007a, b), i.e. ED shifting
appears a fundamental aspect of OCD in a variety of
phenotypic forms. Such an overlap has important im-
plications for understanding the neurobiology of this
complex, disabling disorder and generating new
pharmacological and psychological treatment targets.
Future research, using larger cohorts, may further tap
the richness of schizo-OCD pathology by expanding
into other key neuropsychological areas known to be
implicated in schizophrenia and OCD, such as mem-
ory, motor impulsivity and aﬀective processing.
Conclusion
Using speciﬁc tests of neuro-cognitive processing, we
have demonstrated that schizophrenia patients with
OCD exhibited signiﬁcantly greater impairment on
a task of attentional set-shifting (extra-dimensional
set-shift) compared with a matched group of schizo-
phrenia patients without OCD. Consistent with pre-
vious studies, our ﬁndings implicate impaired
set-shifting, representing cognitive inﬂexibility, as a
candidate trait marker for schizo-OCD.
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